Skip to main
BTSG

BTSG Stock Forecast & Price Target

BTSG Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrightSpring Health Services Inc. has demonstrated robust performance in its OP Rehab segment, with a noted growth rate in the double-digit percentage range, contributing to strong margins. The company has outlined plans to enhance its margins further and significantly boost EBITDA through strategic mergers and acquisitions, positioning itself to expand market share in the generic drug sector. Additionally, ongoing operational initiatives, along with anticipated wins in lower daily dosage (LDD) markets and pending acquisitions, are expected to bolster EBITDA estimates for 2026-2027, supporting a positive long-term outlook for the company's financial health.

Bears say

BrightSpring Health Services Inc. faces potential revenue challenges due to the risk of weakened client budgets, which may adversely impact their business operations. The company is in the process of acquiring 127 home health locations, which is anticipated to provide EBITDA benefits in 2026, though current expectations for growth appear low amid uncertainties in drug pricing and prescription practices. Furthermore, BrightSpring's significant debt load may hinder its capacity for growth investments, while the loss of a contract in 2024 further complicates their expansion opportunities in a competitive market.

BTSG has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BrightSpring Health Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BrightSpring Health Services Inc (BTSG) Forecast

Analysts have given BTSG a Buy based on their latest research and market trends.

According to 9 analysts, BTSG has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BrightSpring Health Services Inc (BTSG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.